Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

Overview of attention for article published in Lancet Oncology, November 2012

Altmetric Badge

21

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 9 X users

wikipedia: 2 Wikipedia pages
f1000: 1 research highlight platform

Citations

dimensions_citation: 467 Dimensions

Readers on

mendeley: 332 Mendeley

Summary News Policy documents X Wikipedia Research highlights Dimensions citations

So far, Altmetric has seen 1 news story.

Pre-Op Aflibercept Ups Response in High-Risk Rectal Cancer

MedPage Today, 29 Aug 2019

The addition of aflibercept (Eylea) to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) induction chemotherapy…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.